Author

M. H. Wang

Observed name: Min-Hui Wang

Institution: AstraZeneca (United States)

Observed institution: AstraZeneca (United States)

OpenAlex ID: A5028126335

P666: Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-naive Chronic Lymphocytic Leukemia: 5-year Follow-up of Elevate-tn

2022 · J. P. Sharman, M. Egyed, et al. · HemaSphere · 4

Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia

2026 · Richard R. Furman, William G. Wierda, et al. · Blood Advances · 1

P668: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/refractory Chronic Lymphocytic Leukemia: Ascend Results at ~4 Years of Follow-up

2022 · P. Ghia, A. Pluta, et al. · HemaSphere · 1

Works count: 3

Citation count: 6

H-index: 1

I10-index: